Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2022-05-06 00:00:00 ET · period of report 2022-05-05 · accession 0000899243-22-017083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-06 | 2022-05-05 | AMLX | Cohen Joshua B | Co-CEO, Dir | M - OptEx | $0.37 | +334.5K | 2.90M | +13% | +$123.8K |
| D | 2022-05-06 | 2022-05-05 | AMLX | Cohen Joshua B | Co-CEO, Dir | M - OptEx | $0.00 | -334.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-05 | M | A | 334,520 | $0.37 | 2,898,585 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-05-05 | M | D | 334,520 | $0.00 | 0 | D | $0.37 · — to 2023-02-16 | 334,520 Common Stock | (F1) This option is fully vested and exercisable. |